Metoprolol Stada

Metoprolol Tartrate, the active ingredient in Metoprolol Stada, is a beta blocker presented as an oral tablet for oral use. It lowers blood pressure, relieves angina, and improves outcomes after myocardial infarction and in chronic heart failure. GNH USA supplies Metoprolol Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metoprolol Stada is a selective β1‑adrenergic blocker used in cardiovascular disease management. - Hypertension: helps lower elevated blood pressure and reduce cardiovascular risk. - Angina pectoris: decreases myocardial oxygen demand, relieving chest pain. - Post‑myocardial infarction: reduces the risk of recurrent ischemic events and improves survival. - Chronic heart failure: improves ventricular function and decreases hospitalisation rates.

Metoprolol Stada may cause a range of adverse reactions.

Common Side Effects: - Fatigue or tiredness - Dizziness or light‑headedness - Headache - Bradycardia (slow heart rate) - Cold extremities - Nausea or upset stomach

Serious or Rare Side Effects: - Severe bradycardia or heart block - Marked hypotension - Bronchospasm, especially in patients with asthma - Allergic reactions including rash or angioedema - Depression or mood changes - Worsening heart failure symptoms

Before initiating therapy, clinicians should consider several safety aspects. - Monitor blood pressure: ensure adequate control without excessive hypotension. - Assess heart rate: watch for bradycardia, especially in patients with conduction disorders. - Use caution in asthma or chronic obstructive pulmonary disease: β1‑selectivity may not fully prevent bronchospasm. - Avoid abrupt discontinuation: taper the dose to prevent rebound tachycardia or hypertension. - Adjust dose in renal impairment: reduced clearance may require lower dosing. - Store at room temperature: keep in the original pack, protect from moisture.

Metoprolol Stada can interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Non‑selective beta‑blockers: additive bradycardia and hypotension. - Calcium channel blockers (verapamil, diltiazem): risk of severe atrioventricular block. - Clonidine: combined effect may cause profound hypotension.

Moderate Interactions (Monitor Closely): - Diuretics: may increase risk of electrolyte disturbances and hypotension. - ACE inhibitors or ARBs: additive blood‑pressure‑lowering effect. - Antidepressants (SSRIs, SNRIs): possible alterations in heart‑rate response.